person · Reporting owner

Ramasastry Saira

Disclosed activity across 9 companies

Tapewire entity: 37277
SEC CIK: 0001547959

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
FILANA THERAPEUTICS, INC.SAVA · Entity 7294	Director	December 13, 2019	December 16, 2019
Faeth Therapeutics, Inc.FTH · Entity 5029	Director	June 12, 2026	June 16, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	Director	June 15, 2026	June 18, 2026
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	February 25, 2022	March 01, 2022
Vir Biotechnology, Inc.VIR · Entity 4522	Director	May 30, 2025	June 02, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

FILANA THERAPEUTICS, INC.

Report date December 13, 2019 · Filed December 16, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2029-12-13	Direct	30,000	Reported balance After 2019-12-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-12-13 · Grant · Acquired 30,000 · Balance 30,000 F1: Stock Options issued pursuant to the Company's Equity Incentive Plan vest over four (4) years at a rate of 1/48th each month.

Filing footnotes · ownership attribution and instrument terms

F1: Stock Options issued pursuant to the Company's Equity Incentive Plan vest over four (4) years at a rate of 1/48th each month.

Faeth Therapeutics, Inc.

Report date June 12, 2026 · Filed June 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.00 · Expires 2036-06-11	Direct	25,000	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Mirum Pharmaceuticals, Inc.

Report date June 15, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14	Direct	3,772	Reported balance After 2026-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,980	Reported balance After 2026-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.

F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.

SANGAMO THERAPEUTICS, INC

Report date February 25, 2022 · Filed March 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	35,700	Reported balance After 2022-02-25 transaction · row 1 1 source row Row 1 · 2022-02-25 · Grant · Acquired 12,500 · Balance 35,700 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2032-02-24	Direct	25,000	Reported balance After 2022-02-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-02-25 · Grant · Acquired 25,000 · Balance 25,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Vir Biotechnology, Inc.

Report date May 30, 2025 · Filed June 02, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	22,619	Reported balance After 2025-05-30 transaction · row 1 1 source row Row 1 · 2025-05-30 · Grant · Acquired 8,000 · Balance 22,619 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 30, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.94 · Expires 2035-05-29	Direct	16,000	Reported balance After 2025-05-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-05-30 · Grant · Acquired 16,000 · Balance 16,000 F3: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

F2: The RSUs will vest in full on May 30, 2026.

F3: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

9 METERS BIOPHARMA, INC.

Report date April 24, 2020 · Filed May 04, 2020

Section 16 reporting ended · disclosed 2020-05-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2030-04-24	Direct	25,000	Reported balance After 2020-04-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-04-24 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vested in full on the grant date, 4/24/2020.

Filing footnotes · ownership attribution and instrument terms

F1: This option vested in full on the grant date, 4/24/2020.

Akouos, Inc.

Report date December 01, 2022 · Filed December 02, 2022

Section 16 reporting ended · disclosed 2022-12-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2032-06-22	Direct	0	Reported balance After 2022-12-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-12-01 · Disposition to issuer · Disposed 16,000 · Balance 0 F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2] F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one nontradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.

Filing footnotes · ownership attribution and instrument terms

F1: At the effective time of the merger (the "Effective Time"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]

F2: [Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one nontradable contingent value right ("CVR") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.

Day One Biopharmaceuticals, Inc.

Report date April 23, 2026 · Filed April 23, 2026

Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-23 transaction · row 1 1 source row Row 1 · 2026-04-23 · Disposition to issuer · Disposed 40,485 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25	Direct	Reported balance After 2026-04-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-23 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25	Direct	Reported balance After 2026-04-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-23 · Disposition to issuer · Disposed 47,581 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-06-20	Direct	Reported balance After 2026-04-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-23 · Disposition to issuer · Disposed 28,700 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-06-21	Direct	Reported balance After 2026-04-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-23 · Disposition to issuer · Disposed 37,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-05-22	Direct	Reported balance After 2026-04-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-23 · Disposition to issuer · Disposed 32,335 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2035-06-01	Direct	Reported balance After 2026-04-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-23 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-23 · Disposition to issuer · Disposed 15,000 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan. F8: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

Filing footnotes · ownership attribution and instrument terms

F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F3: The options are fully vested.

F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F5: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.

F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F7: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan.

F8: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

REPROS THERAPEUTICS INC.

Report date January 29, 2018 · Filed January 31, 2018

Section 16 reporting ended · disclosed 2018-01-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-01-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-01-29 · Other · Disposed 12,221 · Balance 27,779 Row 2 · 2018-01-31 · Disposition to issuer · Disposed 27,779 · Balance 0 F1: Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2) F2: (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2027-09-15	Direct	0	Reported balance After 2018-01-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-01-31 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2)

F2: (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time.

F3: Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor.

F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2026 Filed Jun 18, 2026 00:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantRestricted Stock Units · Derivative	1,980	$0.00	$0.00	Disclosure SEC source: 0001547959-26-000016 · form4-06172026_080616.xml · derivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,980 Underlying: Common Stock · 1,980 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document
June 15, 2026 Filed Jun 18, 2026 00:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	3,772	$0.00 Strike: $101.00	$0.00	Disclosure SEC source: 0001547959-26-000016 · form4-06172026_080616.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,772 Underlying: Common Stock · 3,772 shares Expires 2036-06-14 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:49 UTC	Faeth Therapeutics, Inc. FTH · Entity 5029	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $13.00	$0.00	Disclosure SEC source: 0001547959-26-000015 · form4-06162026_080650.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-06-11 F1 · kind: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document
June 01, 2026 Filed Jun 2, 2026 23:50 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	3,977	$100.00	$397,700.00	Disclosure SEC source: 0001547959-26-000011 · form4-06022026_070603.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
May 29, 2026 Filed Jun 2, 2026 23:50 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionRestricted Stock Units · Derivative	3,977	$0.00	$0.00	Disclosure SEC source: 0001547959-26-000011 · form4-06022026_070603.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,977 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests on May 29, 2026. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests on May 29, 2026. Read SEC document
May 29, 2026 Filed Jun 2, 2026 23:50 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	3,977	Not disclosed	Not disclosed	Disclosure SEC source: 0001547959-26-000011 · form4-06022026_070603.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document
May 15, 2026 Filed May 19, 2026 00:32 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	2,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001547959-26-000009 · form4-05192026_120532.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document
May 15, 2026 Filed May 19, 2026 00:32 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	2,000	$109.47	$218,940.00	Disclosure SEC source: 0001547959-26-000009 · form4-05192026_120532.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
May 15, 2026 Filed May 19, 2026 00:32 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,000	$23.51	$47,020.00	Disclosure SEC source: 0001547959-26-000009 · form4-05192026_120532.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerRestricted Stock Unit (RSU) · Derivative	15,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001547959-26-000008 · form4-04232026_080429.xml · derivative · entry 8 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7 · derivative.exercise_date: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan. F8 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	22,500	Not disclosed Strike: $7.01	Not disclosed	Disclosure SEC source: 0001547959-26-000008 · form4-04232026_080429.xml · derivative · entry 7 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2035-06-01 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	32,335	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001547959-26-000008 · form4-04232026_080429.xml · derivative · entry 6 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	37,500	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001547959-26-000008 · form4-04232026_080429.xml · derivative · entry 5 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2033-06-21 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	28,700	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001547959-26-000008 · form4-04232026_080429.xml · derivative · entry 4 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,700 shares Expires 2032-06-20 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	47,581	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001547959-26-000008 · form4-04232026_080429.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,581 shares Expires 2031-05-25 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	40,000	Not disclosed Strike: $8.99	Not disclosed	Disclosure SEC source: 0001547959-26-000008 · form4-04232026_080429.xml · derivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
April 23, 2026 Filed Apr 23, 2026 20:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerCommon Stock	40,485	Not disclosed	Not disclosed	Disclosure SEC source: 0001547959-26-000008 · form4-04232026_080429.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. Read SEC document
April 15, 2026 Filed Apr 17, 2026 00:40 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	2,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001547959-26-000007 · form4-04172026_120419.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document
April 15, 2026 Filed Apr 17, 2026 00:40 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	2,000	$96.90	$193,800.00	Disclosure SEC source: 0001547959-26-000007 · form4-04172026_120419.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
April 15, 2026 Filed Apr 17, 2026 00:40 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,000	$23.51	$47,020.00	Disclosure SEC source: 0001547959-26-000007 · form4-04172026_120419.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2026 Filed Mar 17, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	2,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001547959-26-000006 · form4-03172026_070313.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document
March 16, 2026 Filed Mar 17, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	2,000	$90.76	$181,520.00	Disclosure SEC source: 0001547959-26-000006 · form4-03172026_070313.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
March 16, 2026 Filed Mar 17, 2026 23:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,000	$23.51	$47,020.00	Disclosure SEC source: 0001547959-26-000006 · form4-03172026_070313.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 13, 2026 Filed Feb 17, 2026 21:38 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	2,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001547959-26-000005 · form4-02172026_090212.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document
February 13, 2026 Filed Feb 17, 2026 21:38 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	2,000	$102.09	$204,180.00	Disclosure SEC source: 0001547959-26-000005 · form4-02172026_090212.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
February 13, 2026 Filed Feb 17, 2026 21:38 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,000	$23.51	$47,020.00	Disclosure SEC source: 0001547959-26-000005 · form4-02172026_090212.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 15, 2026 Filed Jan 16, 2026 21:05 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	2,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001547959-26-000002 · form4-01162026_090102.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 2,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document
January 15, 2026 Filed Jan 16, 2026 21:05 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	2,000	$90.99	$181,980.00	Disclosure SEC source: 0001547959-26-000002 · form4-01162026_090102.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
January 15, 2026 Filed Jan 16, 2026 21:05 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,000	$23.51	$47,020.00	Disclosure SEC source: 0001547959-26-000002 · form4-01162026_090102.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 22, 2025 Filed Dec 23, 2025 23:52 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001547959-25-000008 · form4-12232025_111209.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document
December 22, 2025 Filed Dec 23, 2025 23:52 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	5,000	$80.00	$400,000.00	Disclosure SEC source: 0001547959-25-000008 · form4-12232025_111209.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
December 22, 2025 Filed Dec 23, 2025 23:52 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	5,000	$23.51	$117,550.00	Disclosure SEC source: 0001547959-25-000008 · form4-12232025_111209.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2025 Filed Dec 19, 2025 21:15 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	2,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001547959-25-000007 · form4-12192025_091243.xml · derivative · entry 4 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 2,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document
December 18, 2025 Filed Dec 19, 2025 21:15 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	1,000	$70.00	$70,000.00	Disclosure SEC source: 0001547959-25-000007 · form4-12192025_091243.xml · nonDerivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
December 18, 2025 Filed Dec 19, 2025 21:15 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	1,000	$69.46	$69,460.00	Disclosure SEC source: 0001547959-25-000007 · form4-12192025_091243.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. Read SEC document
December 18, 2025 Filed Dec 19, 2025 21:15 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	2,000	$23.51	$47,020.00	Disclosure SEC source: 0001547959-25-000007 · form4-12192025_091243.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	32,335	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 10 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,335 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	32,335	$0.00 Strike: $13.87	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 9 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	37,500	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 8 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2033-06-21 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	37,500	$0.00 Strike: $12.69	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 7 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2033-06-21 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	28,700	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 6 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,700 Underlying: Common Stock · 28,700 shares Expires 2032-06-20 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	28,700	$0.00 Strike: $16.29	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 5 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,700 shares Expires 2032-06-20 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	47,581	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 4 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,581 Underlying: Common Stock · 47,581 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	47,581	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,581 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	40,000	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
November 06, 2025 Filed Nov 7, 2025 23:04 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Disposition to issuerStock Option (right to buy Common Stock) · Derivative	40,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001547959-25-000005 · form4-11072025_111134.xml · derivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document
September 08, 2025 Filed Sep 10, 2025 21:50 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	17,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001415889-25-024128 · form4-09102025_090933.xml · derivative · entry 3 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document
September 08, 2025 Filed Sep 10, 2025 21:50 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	SaleCommon Stock	17,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-024128 · form4-09102025_090933.xml · nonDerivative · entry 2 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The weighted average sale price for the transaction reported was $77.042178, and the range of prices were between $76.835 and $77.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document
September 08, 2025 Filed Sep 10, 2025 21:50 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionCommon Stock	17,000	$23.51	$399,670.00	Disclosure SEC source: 0001415889-25-024128 · form4-09102025_090933.xml · nonDerivative · entry 1 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 03, 2025 Filed Jun 4, 2025 20:11 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	Exercise / conversionStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $14.12	$0.00	Disclosure SEC source: 0001415889-25-015570 · form4-06042025_080640.xml · derivative · entry 4 Ramasastry Saira · CIK 0001547959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2031-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.